Search

UCB SA

Closed

160.55 0.34

Overview

Share price change

24h

Current

Min

160.55

Max

161.5

Key metrics

By Trading Economics

Income

104M

Sales

127M

2.8B

P/E

Sector Avg

26.67

EPS

2.09

Profit margin

3.728

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+19.23 upside

Market Stats

By TradingEconomics

Market Cap

-180M

31B

Previous open

160.21

Previous close

160.55

News Sentiment

By Acuity

17%

83%

UCB SA Chart

Related News

5 Dec 2023, 16:47 UTC

Market Talk

European Pharmas With New Drugs Hold Most Promise in 2024 -- Market Talk

UCB SA Forecast

Price Target

By TipRanks

19.23% upside

12 Months Forecast

Average 94.86 EUR  19.23%

High 125 EUR

Low 74 EUR

Based on 7 Wall Street analysts offering 12 month price targets forUCB SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

4

Buy

1

Hold

2

Sell

Sentiment

By Acuity

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About UCB SA

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.